세포 및 유전자 치료 시장 규모, 점유율, 성장 분석(치료 유형별, 치료 클래스별, 전달 수단별, 최종사용자별, 지역별) : 산업 예측(2024-2031년)

Global Cell and Gene Therapy Market size was valued at USD 17.7 billion in 2022 and is poised to grow from USD 20.97 billion in 2023 to USD 81.55 billion by 2031, growing at a CAGR of 18.50% during the forecast period (2024-2031).

The cell and gene therapy market is set to experience significant growth in the coming years, driven by advancements in genetic engineering and increased investments in cellular research. The expanding application of innovative cell and gene therapies for a range of diseases presents new opportunities for industry players. A heightened focus on enhancing patient care, coupled with the rising demand for advanced treatment options and the growing prevalence of chronic diseases, are pivotal factors propelling market expansion. Additionally, the trend towards personalized medicine and the increasing rate of regulatory approvals for groundbreaking therapies further pave the way for new business prospects within this sector. However, the market does face challenges, namely the high costs associated with advanced therapies, limited reimbursement options, and restricted access to novel treatments, which may hinder broader adoption of these innovative solutions. Addressing these constraints will be essential for realizing the full potential of the cell and gene therapy market, positioning it as a key area for future healthcare advancements. Overall, the combination of technological innovation and evolving patient needs suggests a promising trajectory for the cell and gene therapy landscape, making it an appealing area for investment and development in the healthcare industry.

Top-down and bottom-up approaches were used to estimate and validate the size of the Global Cell And Gene Therapy market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Global Cell And Gene Therapy Market Segmental Analysis

Global Cell and Gene Therapy Market is segmented by Therapy Type, Therapeutic class, Delivery Method, End-Users, and region. Based on Therapy Type, the market is segmented into Cell Therapy, Stem Cells (T Cells, Dendritic Cells, NK Cells, Tumor Cells), Gene Therapy (Gene Silencing, Cell Replacement, Gene Augmentation, Other Therapies). Based on Therapeutic class, the market is segmented into Cardiovascular Disease, Cancer, Genetic Disorder, Rare Diseases, Oncology, Hematology, Ophthalmology, Infectious Disease, Neurological Disorders, and Others. Based on Delivery Method, the market is segmented into In Vivo, and Ex Vivo. Based on End-Users, the market is segmented into Hospitals, Cancer Care Centers, and Others. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & and Africa.

Driver of the Global Cell And Gene Therapy Market

Advancements in gene technologies are a significant market driver for the Global Cell and Gene Therapy market. These innovations, including CRISPR, recombinant DNA technology, and next-generation sequencing, have enhanced the precision and efficacy of gene editing and modification, paving the way for targeted therapies. With the increasing prevalence of genetic disorders, cancer, and rare diseases, these advanced technologies facilitate the development of more personalized and effective treatment options. Furthermore, ongoing research and investment in biopharmaceuticals are accelerating the translation of these technologies from the lab to clinical applications, propelling market growth and attracting both public and private funding.

Restraints in the Global Cell And Gene Therapy Market

One of the significant market restraints for the global cell and gene therapy market is the prohibitively high costs associated with these treatments. The complex and specialized nature of developing gene and cell therapies often results in substantial research and development expenditures, which are subsequently passed on to patients. This financial barrier limits access for a considerable segment of the population, potentially leading to disparities in treatment availability. Additionally, the high price tag poses challenges for healthcare providers and payers in terms of reimbursement and health insurance coverage, ultimately hindering market growth and patient adoption of these innovative therapies.

Market Trends of the Global Cell And Gene Therapy Market

The Global Cell and Gene Therapy market is witnessing a notable trend towards the increasing demand for combination therapies, which integrate the advantages of both gene and cell therapies. This trend is driven by a growing recognition of the high efficacy these integrated approaches offer in treating complex and multifaceted medical conditions. As healthcare professionals and patients alike seek more effective treatment options, cell and gene therapy companies are urged to innovate and develop novel combination therapies. This focus aims to enhance patient outcomes across a variety of disease indications, thereby positioning companies favorably within a rapidly evolving biopharmaceutical landscape.

Table of Contents

Introduction

• Objectives of the Study
• Definitions
• Market Scope

Research Methodology

• Information Procurement
• Secondary & Primary Data Sources
• Market Size Estimation
• Market Assumptions & Limitations

Executive Summary

• Market Overview Outlook
• Supply Demand Trend Analysis
• Segmental Opportunity Analysis

Market Dynamics & Outlook

• Market Dynamics
  • Drivers
  • Opportunities
  • Restraints
  • Challenges
• Porters Analysis
  • Competitive rivalry
  • Threat of Substitute Products
  • Bargaining Power of Buyers
  • Threat of New Entrants
  • Bargaining Power of Suppliers

Key Market Insights

• Technology Analysis
• Value Chain Analysis
• Ecosystem of the Market
• Case study Analysis
• Regulatory Landscape
• Top Investment Analysis
• Key Success Factor
• Degree of Competition
• Market Attractiveness Index, 2023

Cell and Gene Therapy Market by Therapy Type

• Market Overview
• Cell Therapy
  • Stem Cells
  • T Cells
  • Dendritic Cells
  • NK Cells
  • Tumor Cells
• Gene Therapy
  • Gene Silencing
  • Cell Replacement
  • Gene Augmentation
  • Other Therapies

Cell and Gene Therapy Market by Therapeutic class

• Market Overview
• Cardiovascular Disease
• Cancer
• Genetic Disorder
• Rare Diseases
• Oncology
• Hematology
• Ophthalmology
• Infectious Disease
• Neurological Disorders
• Others

Cell and Gene Therapy Market by Delivery Method

• Market Overview
• In Vivo
• Ex Vivo

Cell and Gene Therapy Market by End-Users

• Market Overview
• Hospitals
• Cancer Care Centers
• Others

Cell and Gene Therapy Market Size by Region

• Market Overview
• North America
  • USA
  • Canada
• Europe
  • Germany
  • Spain
  • France
  • UK
  • Italy
  • Rest of Europe
• Asia Pacific
  • China
  • India
  • Japan
  • South Korea
  • Rest of Asia-Pacific
• Latin America
  • Brazil
  • Rest of Latin America
• Middle East & Africa (MEA)
  • GCC Countries
  • South Africa
  • Rest of MEA

Competitive Landscape

• Top 5 Player Comparison
• Market Positioning of Key Players, 2023
• Strategies Adopted by Key Market Players
• Recent Activities in the Market
• Key Companies Market Share (%), 2023

Key Company Profiles

• Alnylam Pharmaceuticals Inc. (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Amgen Inc. (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Biogen Inc. (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• CORESTEM Inc. (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Helixmith Co. Ltd. (South Korea)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• JCR Pharmaceuticals Co. Ltd. (Japan)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Kolon TissueGene Inc. (South Korea)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Novartis AG (Switzerland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Pfizer Inc. (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Gilead Sciences, Inc. (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Sangamo Therapeutics, Inc. (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Bluebird Bio, Inc. (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Zymeworks Inc. (Canada)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• CRISPR Therapeutics AG (Switzerland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Celyad Oncology SA (Belgium)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Atara Biotherapeutics, Inc. (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Athenex, Inc. (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Bristol Myers Squibb (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Kyowa Kirin (Japan)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Sanofi (France)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments